Research Study Search Tool

Use our HBOC Research Search tool to find and participate in research focused on hereditaty cancers. Need assistance getting started?

Search Results: Treatment + Breast Cancer (9 results)

Here are some research studies that may be enrolling patients like you. Please check with the study contact and your health care provider to confirm your eligibility and see if the study is right for you. Note, our search tool may not be comprehensive and additional research resources can be found here.

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

Treatment:
Breast

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

Olaparib Expanded is a study looking at whether the drug Olaparib is effective treatment for people with certain types of metastatic breast cancer.  Olaparib belongs to a class of drugs known as PARP inhibitors. PARP inhibitors are particularly effective for treating tumors in people with an inherited BRCA mutation. This study is looking at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation.

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden

Treatment:
Breast
Ovarian
Pancreatic
Prostate

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden

This study is researching a combination of two immunotherapy drugs for advanced solid tumors that contain a tumor biomarker known as "High Tumor Mutation Burden" (TMB-H). The researchers are studying whether treatment  of these tumors with a combination of the drugs nivolumab plus ipilimumab is safe and effective compared with nivolumab alone. 

A Study in Advanced Breast Cancer Patients with BRCA 1/2 Mutations Evaluating Olaparib alone or in Combination with Atezolizumab

Treatment:
Breast

A Study in Advanced Breast Cancer Patients with BRCA 1/2 Mutations Evaluating Olaparib alone or in Combination with Atezolizumab

This is a study for women or men who have been diagnosed with advanced breast cancer with a BRCA 1/2 mutation. The goal of the study is to look at whether giving the PARP inhibitor olaparib in combination with the immunotherapy atezolizumab improves outcomes for patients compared to olaparib alone.  

 

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

Treatment:
Breast
Ovarian
Prostate

Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors

The purpose of the study is to examine the anti-tumor activity and safety of the immuno-onology agent, avelumab in combination with the PARP inhibitor, talazoparib in patients with locally advanced  or metastatic triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, castration resistant prostate cancer (CRPC) solid, non-small cell lung cancer (NSCLC), and urothelial cancer (UC). The study is also open to people with other advanced solid tumors with a BRCA or ATM gene defect

A Phase II Study to Evaluate the Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib in Patients with a BRCA or ATM Mutation

Treatment:
Breast
Ovarian
Pancreatic

A Phase II Study to Evaluate the Safety and Anti-tumor Activity of Avelumab in Combination with Talazoparib in Patients with a BRCA or ATM Mutation

This study is looking at how well two cancer drugs work together to treat certain advanced cancers. 

The researchers want to learn how safe and effective the combination of an immunotherapy (known as Avelumab) and a PARP inhibitor (known as Talazoparib) is for treating patients with locally advanced or metastatic solid tumors with a BRCA1, BRCA2, or ATM gene defect.

Pembrolizumab in Advanced BRCA-mutated Breast Cancer

Treatment:
Breast

Pembrolizumab in Advanced BRCA-mutated Breast Cancer

 

This trial will evaluate the use of immunotherapy in people with advanced breast cancer associated with a BRCA mutation. The main objective is to examine overall response rate of pembrolizumab (immunotherapy) single agent therapy in advanced BRCA-mutated breast cancer.

Visit clinicaltrials.gov for more information. 

Talazoparib Beyond BRCA (TBB) Trial

Treatment:
Breast

Talazoparib Beyond BRCA (TBB) Trial

The goal of the study is to evaluate the anti-cancer activity of Talazoparib (a type of treatment known as a PARP inhibitor) in patients with advanced breast cancer with specific genetic mutations based on a blood, saliva, or tumor test. See the clinicaltrials.gov listing for additional information. 

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa (Inform)

Treatment:
Breast

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa (Inform)

About the Study

INFORM is a study for patients newly diagnosed with breast cancer who have a BRCA1 or BRCA2 mutation. The study is evaluating whether the chemotherapy drug Cisplatin is better than currently used standard chemotherapy drugs (Cyclophosphamide/Doxorubicin) for treating patients with newly diagnosed breast cancer due to an inherited mutation in BRCA1 or BRCA2. 

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation:  A Radiotherapy Comparative Effectiveness Trial

Treatment:
Breast

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial

The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a nationwide clinical study comparing two FDA approved radiation therapies for the treatment of breast cancer, PHoton Therapy vs. PRoton Therapy. With any radiation treatment to the breast, the heart may be exposed to radiation potentially resulting in heart problems in the future. Both Photon and Proton therapies are FDA approved; however, to date doctors do not know which therapy is better or worse in terms of reducing side effects and promoting length and quality of life after radiation.

We hope to learn: The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety. These objectives were chosen as study priorities by breast cancer patients themselves.

For more information, visit: RadComp.org

Additional Results on Clinicaltrials.gov: Treatment + Breast Cancer

501 Results

Clinical Trial Official Title
NCT03643861 RAD 1802: Pilot Trial of LINAC Based Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
NCT03043794 Study of Stereotactic Radiotherapy for Breast Cancer
NCT02958774 Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation
NCT02482376 Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer
NCT00909909 Radiation Therapy in Treating Women With Early Stage Breast Cancer
NCT02900469 Presurgical Trial of Denosumab in Breast Cancer
NCT03137693 Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer
NCT03958721 Capecitabine and Radiotherapy in the Adjuvant Treatment of Resistant Breast Cancer
NCT03460067 Omission of Radiation in Patients With Her-2 Positive Breast Cancer
NCT02977468 Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT02685332 Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA
NCT03524170 Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT02653755 The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer
NCT03612648 Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma
NCT02276885 Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial
NCT03366844 Breast Cancer Study of Preoperative Pembrolizumab + Radiation
NCT03786354 Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients With Lymph-Node Positive Breast Cancer
NCT03345420 Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
NCT03807765 Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
NCT02912312 Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
NCT03945721 A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Patients With Triple Negative Breast Cancer and an Incomplete Pathologic Response
NCT02728076 MRI-Based Preoperative Accelerated Partial Breast Irradiation
NCT03359954 Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT02694029 Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer
NCT03167359 Hypofractionated Radiotherapy in Breast Cancer
NCT02515110 Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer
NCT01980823 Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer
NCT03483012 Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis
NCT02927912 Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
NCT03909282 Phase II Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT02917421 Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations
NCT02400658 Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer
NCT03624478 Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery
NCT03324802 Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery
NCT03789097 Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT03916068 Acute Post-Radiation Hyperbaric Oxygen (HBO2) for Breast Cancer Patients Who Have Recently Completed Radiation Therapy
NCT03546686 Peri-Operative Ipilimumab+Nivolumab and Cryoablation Versus Standard Care in Women With Triple-negative Breast Cancer
NCT01839838 APBI Proton Feasibility and Phase II Study
NCT03411070 SCOUT Reflector for Tagging Lymph Nodes for Targeted Removal in Patients With Breast Cancer
NCT01688388 Single Fraction Intraoperative Radiotherapy
NCT02876640 Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer
NCT01245712 Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
NCT02315196 Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer
NCT03102866 Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer
NCT03387553 HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
NCT01618357 Pre-Operative Radiation and Veliparib for Breast Cancer
NCT02926729 Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT00734838 Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy
NCT02827877 Copper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer
NCT03216421 Intraoperative Radiation Therapy (IORT) in DCIS
NCT01766297 Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT03747042 Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
NCT03012399 Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery
NCT02755896 Trial to Compare Radiation Fibrosis With Five Versus Three Fractions
NCT03567044 Immune Effects in Patients Treated With Whole Breast Irradiation
NCT03581136 Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod
NCT03774472 Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Participants With Estrogen Receptor Positive, HER2 Negative Breast Cancer
NCT03261323 Breast Reconstruction Following Breast Cancer in Very High Risk Patients
NCT00625417 Optical Spectroscopy in Evaluating Tumor Margins in Patients Who Have Undergone Surgery for Breast Tumors
NCT02971748 Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy
NCT02658812 Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
NCT01185132 Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
NCT03004183 SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC
NCT03112590 Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
NCT02689427 Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
NCT03564782 Examining Bioactivity of PVSRIPO in Triple Negative Breast Cancer
NCT03375892 A Phase II Study of the Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure
NCT03765983 GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases
NCT02760030 Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
NCT02734979 Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema
NCT03632941 A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer
NCT01750073 Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer
NCT03911453 Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors
NCT04024800 Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
NCT03422003 Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma
NCT03542175 A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
NCT03598257 Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer
NCT03077841 Optimizing Preventative Adjuvant Linac-Based Radiation: the OPAL Trial - Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
NCT03488693 Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
NCT02823262 A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older
NCT03084536 PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery
NCT03990610 An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction
NCT03796273 Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
NCT03473639 A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy
NCT01901094 Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy
NCT03655600 Acupressure for Pain and Opioid Use Among Breast Cancer Patients
NCT01792726 A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.
NCT04041128 PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
NCT01724606 Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)
NCT03562273 GammaPod Registry and Quality of Life Nomogram
NCT01897441 Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer
NCT04020575 Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
NCT02422498 Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
NCT02564848 Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65
NCT02530489 Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
NCT01570998 Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery
NCT03093350 TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer
NCT02781805 Pilot Study of Bisphosphonates for Breast Cancer
NCT04054986 Study of the Imaging Agent 18F-Var3 in Patients With Breast Cancer
NCT02623972 A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
NCT02348320 Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
NCT02520063 Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer
NCT02744079 Comparison of Healthy Diets on Breast Cancer Markers
NCT02789657 BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.
NCT01872975 Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery
NCT01928589 Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer
NCT02540330 A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
NCT01723774 PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer
NCT03354611 Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging
NCT03362060 PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer
NCT02603341 Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
NCT02364557 Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer
NCT02332928 Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy
NCT03941730 Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer
NCT02779855 Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
NCT02411656 Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
NCT02427581 Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02945579 Eliminating Surgery After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer
NCT02395614 Surgical Site Infection With 0.05% Chlorhexidine (CHG) Compared to Triple Antibiotic Irrigation
NCT02204098 Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy
NCT03992131 A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)
NCT02536794 MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
NCT02479230 Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients
NCT03801369 Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer
NCT02938442 Vaccination of Triple Negative Breast Cancer Patients
NCT03941756 Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer
NCT03691493 Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis
NCT03766009 Increasing Patients' Engagement in Breast Cancer Surgery Decision-Making
NCT03106415 Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
NCT03213041 Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT03122444 Imipramine on Triple Negative Breast Cancer
NCT03574194 Methionine-Restricted Diet to Potentiate The Effects of Radiation Therapy
NCT03101748 Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
NCT02157051 Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer
NCT01805076 MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer
NCT03955991 VSMART (Video-Conference Stress Management and Relaxation Training for Older Women With Breast Cancer)
NCT03916744 A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
NCT02891759 Compare Outcomes Between Two Acellular Dermal Matrices
NCT04084730 Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
NCT03361800 Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC
NCT00948285 Importance of Magnetic Resonance Imaging (MRI) in Treating Breast Cancer
NCT02456857 Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
NCT03573648 Neoadjuvant Tamoxifen, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer
NCT02780401 Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
NCT03219476 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance
NCT03775850 A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
NCT03694756 TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT03725059 Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
NCT03281954 Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo
NCT03199040 Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
NCT04003038 Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
NCT04049214 Perioperative Mindfulness Proposal
NCT03628066 Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NCT03414970 Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
NCT03358511 Engineering Gut Microbiome to Target Breast Cancer
NCT02927249 Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy
NCT03834532 Living Well After Breast Surgery
NCT02639026 Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers
NCT03808337 Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT02415387 Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer
NCT03113825 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery
NCT03573661 A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers
NCT02954874 Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
NCT03808662 Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
NCT02642094 Aging Mammary Stem Cells and Breast Cancer Prevention
NCT03654547 Safety of TT-00420 Monotherapy in Patients With Advanced Solid Tumors and Triple Negative Breast Cancer
NCT03511079 Music as a Perioperative Therapy in Breast Cancer Patients
NCT03596073 Topical Calcipotriene Treatment for Breast Cancer Immunoprevention
NCT02876107 Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
NCT03684408 Radiofrequency Chip for Localization of Non-Palpable Breast Lesions
NCT03186937 A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer
NCT02907918 Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer
NCT03789110 NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
NCT03135782 Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy
NCT03572374 Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT03179904 FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer
NCT03237572 Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer
NCT03272334 Her2-BATS and Pembrolizumab in Metastatic Breast Cancer
NCT03747120 Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab
NCT03630809 Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
NCT01676753 Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer
NCT03379428 Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer
NCT02593175 Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
NCT03822312 A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy
NCT03096418 Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
NCT01920061 A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
NCT03449238 Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT03393117 Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction
NCT02996825 Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
NCT03718455 Evaluation of Magseed as Localization Device for Biopsy Proven Metastatic Axillary Lymph Nodes
NCT02883387 CT-Angiography Prior to DIEP Flap Breast Reconstruction
NCT03317405 Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
NCT03742102 A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer.
NCT03599453 Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
NCT03149081 A "Window Trial" on Boswellia for Breast Cancer Primary Tumors
NCT03567720 Intratumoral Tavo and Pembro in Patients With Inoperable Locally Advanced or Metastatic TNBC (KEYNOTE-890)
NCT03095352 Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
NCT02453620 Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
NCT03135171 Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
NCT01943695 Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer
NCT02744053 DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer
NCT02264678 Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents
NCT03292198 Subclinical Lymphedema Treatment Study
NCT03256344 Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
NCT03796559 Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT03952325 Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Patients With HER2 Negative MBC
NCT03094052 Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy
NCT03281720 Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases
NCT04086394 Use of PECS Block in Partial Mastectomy for Postoperative Pain Control and Mitigation of Narcotic Use- A Randomized Control Trial
NCT03168737 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients
NCT03535506 Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery
NCT03323658 Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
NCT03971409 Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer
NCT02335671 Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy
NCT03504865 Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo
NCT03351348 Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
NCT03070340 Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery
NCT03428802 Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
NCT03523585 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
NCT03716180 DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
NCT03384914 Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer
NCT03781063 Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer With an ESR1 Mutation
NCT03734029 Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03321045 PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
NCT03562637 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy.
NCT03328026 Combination Study of SV-BR-1-GM in Combination With INCMGA00012 and Epacadostat
NCT02571530 Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer
NCT01494662 HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
NCT03674827 A Study To Evaluate Escalating Doses of A Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
NCT03504488 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors
NCT02898207 Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
NCT03960463 EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds
NCT03653988 Comparison of Pre-op and Post-op Pectoralis Nerve Block
NCT03858972 Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
NCT03364348 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
NCT02792114 T-Cell Therapy for Advanced Breast Cancer
NCT02013492 Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery
NCT03303846 Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients
NCT01376505 Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
NCT03566485 Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer
NCT03726879 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
NCT03417544 Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
NCT03202316 Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer
NCT03641755 Olaparib + Sapacitabine in BRCA Mutant Breast Cancer
NCT03433313 Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer
NCT03301350 Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
NCT04025216 A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
NCT03983395 Study of GBR 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer
NCT01295723 Intraoperative Boost Radiotherapy With Electrons (IOERT) Followed By Hypofractionated Whole-Breast Irradiation (WBRT)
NCT02401347 Phase II Talazoparib in BRCA1 +BRCA2 Wild-Type &Triple-Neg /HER2-Negative Breast Cancer /SolidTumors
NCT02706392 Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
NCT03152929 Paravertebral Block Versus Pectoral Nerve Block
NCT03075072 Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-20 Brain Metastases: A Phase III, Randomized Clinical Trial
NCT03849469 A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
NCT02791581 Understanding and Predicting Breast Cancer Events After Treatment
NCT03501979 Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
NCT03414684 Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
NCT03955640 Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences
NCT01174121 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT03576131 GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors
NCT02778685 Pembrolizumab, Letrozole, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
NCT03321981 MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer
NCT03639948 Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
NCT03199885 Paclitaxel, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Patients With Metastatic Breast Cancer
NCT03262935 SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT02599363 A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer
NCT02489448 Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
NCT02999477 A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
NCT02776917 Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
NCT02734290 Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
NCT03674112 A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
NCT03535701 Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer
NCT03094169 AVID100 in Advanced Epithelial Carcinomas
NCT03549000 A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
NCT02608216 [18F]FLT PET/CT in Rb+ Metastatic Breast Cancer
NCT04083963 Phase 2 Trial of Neoadjuvant Weekly Carboplatin Plus Paclitaxel in Triple Negative Breast Cancer
NCT03027063 Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.
NCT03538028 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
NCT03552718 QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.
NCT03499899 A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer
NCT03012100 Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
NCT03650894 Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
NCT01552434 Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
NCT02124902 Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
NCT03125928 Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer
NCT03735680 A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer
NCT03911973 Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
NCT03959891 AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
NCT03874325 Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
NCT01976169 Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
NCT03018080 Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer
NCT03032107 A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
NCT03344536 A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
NCT02900664 A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
NCT02626507 Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer
NCT03193853 TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer
NCT03761914 Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
NCT02788981 Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
NCT03032406 CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer
NCT03167619 Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)
NCT02595372 Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
NCT03487666 OXEL: Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease
NCT02913430 Phase II Treatment of Metastatic Breast Cancer With Fulvestrant Plus Palbociclib or Tamoxifen Plus Palbociclib
NCT03853707 Ipatasertib and Carboplatin With or Without Paclitaxel in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT02993159 Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
NCT03950570 ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
NCT03329378 Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
NCT02942355 Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer
NCT03514121 FPA150 in Patients With Advanced Solid Tumors
NCT01967823 T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
NCT03742349 Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
NCT02390427 Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
NCT02111850 T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
NCT02188745 ER Reactivation Therapy for Breast Cancer
NCT02830724 Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT02672475 Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer
NCT03412877 Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer
NCT02648477 Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
NCT03190967 T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
NCT02871791 Palbociclib With Everolimus + Exemestane In BC
NCT03964532 TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
NCT03218826 PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
NCT03393845 Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
NCT03858322 'ADVANCE' (A Pilot Trial)
NCT03975647 A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
NCT02436993 Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab
NCT02953860 Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
NCT02531932 Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer
NCT03435952 Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT
NCT02824575 Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer
NCT02955394 Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
NCT02476786 Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT02106598 Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases
NCT03604315 Fluorine F 18 Fluorthanatrace PET/CT in Treating Patients With Primary or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03854903 WI231696: ASPIRE Bosutinib
NCT03941743 Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer
NCT03007979 Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer
NCT04023110 Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab
NCT03154281 Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast
NCT02936206 Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
NCT03367572 Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer
NCT02957968 Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca
NCT03797326 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)
NCT02619669 Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
NCT02834403 L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
NCT03685175 Effect of Cardiotoxic Anticancer Chemotherapy on the Metabolism of [1-13C]Pyruvate in Cardiac Mitochondria
NCT03872388 Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
NCT03962647 A 2-Week Ketogenic Diet in Combination With Letrozole to Modulate PI3K Signaling in ER+ Breast Cancer
NCT03294694 Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer
NCT02910219 Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients
NCT01969643 A Safety Study of SGN-LIV1A in Breast Cancer Patients
NCT03377387 Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
NCT03725436 ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors
NCT03439735 Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC
NCT02095184 GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
NCT03310957 Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer
NCT02538484 Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects
NCT02422641 Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT03206203 Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer
NCT03471663 A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
NCT03326674 Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC
NCT03838367 Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC
NCT02694809 The PROMISE Study: Duavee in Women With DCIS
NCT03409458 A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab
NCT03901469 A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer
NCT03764943 Immunonutrition and Carbohydrate Loading Strategies in Breast Reconstruction
NCT03579472 M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT02890368 Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
NCT02474173 Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
NCT02890069 A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
NCT02393794 Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT01351103 A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
NCT01042379 I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT03878524 A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia
NCT03709082 Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT01989546 Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
NCT01554371 Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies
NCT03499353 Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer
NCT02595320 Capecitabine in Metastatic Breast and GI Cancers
NCT02445391 Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
NCT03616587 Study of AZD9833 Alone or in Combination With Palbociclib in Women With Advanced Breast Cancer
NCT03319459 FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
NCT02738866 Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor
NCT03517488 A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
NCT03879629 TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol
NCT03752398 A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
NCT02872025 Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)
NCT02484404 Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers
NCT02897375 Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
NCT03344965 Olaparib In Metastatic Breast Cancer
NCT03865992 Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease
NCT02755272 A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
NCT02627274 A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
NCT03330847 To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT03587740 ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer
NCT03238495 Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
NCT02876302 Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
NCT03238196 Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer
NCT03326102 Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer
NCT03304080 Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast
NCT01037790 PHASE II TRIAL OF THE CYCLIN-DEPEDENT KINASE INHIBITOR PD 0332991 IN PATIENTS WITH CANCER
NCT03414658 The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer
NCT03162627 Selumetinib and Olaparib in Solid Tumors
NCT03529110 DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
NCT02983045 A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors
NCT03498716 A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
NCT02236000 A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer
NCT03560531 A Study of ZN-c5 in Subjects With Breast Cancer
NCT02947685 Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
NCT02605486 Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)
NCT03424005 A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer (Morpheus-TNBC)
NCT03289039 Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer
NCT02057133 A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
NCT02764541 Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)
NCT02915744 A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
NCT03642990 NR in Chemo-induced Peripheral Neuropathy
NCT03875313 Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
NCT04031885 A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
NCT03822468 Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
NCT03241810 Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer
NCT03280563 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
NCT01670877 Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
NCT03056755 Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
NCT03778931 Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer
NCT02684032 A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer
NCT02632045 Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
NCT03337724 A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT03125902 A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)
NCT03454451 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers
NCT02206984 Endocrine Response in Women With Invasive Lobular Breast Cancer
NCT04060342 GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
NCT03901339 Study of IMMU-132 in HR+/HER2- MBC (TROPICS-02)
NCT03147287 Palbociclib After CDK and Endocrine Therapy (PACE)
NCT03058289 A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
NCT03530696 T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer
NCT03659136 The XENERA™-1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Post-menopausal Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread
NCT03310541 AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations
NCT03633331 Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer
NCT03006172 To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
NCT03371017 A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
NCT02107703 A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer
NCT03584009 A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
NCT03800836 A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer
NCT03054363 Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
NCT03667716 COM701 in Subjects With Advanced Solid Tumors
NCT03719326 A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies
NCT02488967 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT03997123 Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
NCT02637531 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
NCT03435640 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT03099174 This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
NCT02926911 Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS
NCT02860000 Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer
NCT02668666 Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
NCT02964507 Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer
NCT02760849 Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations
NCT03514433 Translating Research Into Practice
NCT03284957 Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer
NCT03332797 A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
NCT04001829 Docetaxel or Paclitaxel in Reducing Chemotherapy-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer
NCT02849496 Olaparib With or Without Atezolizumab in Treating Patients With Locally Advanced Unresectable or Metastatic Non-HER2-Positive Breast Cancer
NCT03829436 TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers
NCT02655822 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers
NCT03289962 A Study of RO7198457 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
NCT03650348 PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors
NCT03970382 A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
NCT03523572 Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer
NCT03680560 Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
NCT03861403 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
NCT03170960 Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03011684 Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
NCT03518138 Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor
NCT03840200 A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.
NCT03829501 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
NCT03524430 RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy BREVITY
NCT03841110 FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
NCT03063619 Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast
NCT03134638 A Study of SY-1365 in Adult Patients With Advanced Solid Tumors
NCT02791334 A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
NCT03893955 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03678883 9-ING-41 in Patients With Advanced Cancers
NCT02498613 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
NCT03674567 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
NCT03717415 A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
NCT02632448 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT02414269 Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
NCT03129139 A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
NCT03565445 A Study of ASP1948, Targeting an Immune Modulatory Receptor, in Subjects With Advanced Solid Tumors
NCT02643303 A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers
NCT03150810 Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT03330405 Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
NCT03126110 Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
NCT02393248 Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
NCT03000257 A Study of ABBV-181 in Participants With Advanced Solid Tumors
NCT03601897 A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
NCT03102320 Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
NCT03595059 A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors
NCT02892123 Trial of ZW25 in Patients With Advanced HER2-expressing Cancers
NCT02734004 A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

FORCE:Facing Our Risk of Cancer Empowered